No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SF240719C90000
- 0.35
- +0.15+75.00%
15min DelayClose Jul 1 16:00 ET
0.35High0.30Low
0.30Open0.20Pre Close2 Volume299 Open Interest90.00Strike Price65.00Turnover27.18%IV7.71%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.1387Delta0.0434Gamma239.66Leverage Ratio-0.0323Theta0.0056Rho33.25Eff Leverage0.0414Vega
Intraday
- 5D
- Daily
News
TD Cowen Maintains Stifel Financial(SF.US) With Buy Rating, Maintains Target Price $94
TD Cowen analyst William Katz maintains $Stifel Financial(SF.US)$ with a buy rating, and maintains the target price at $94.According to TipRanks data, the analyst has a success rate of 61.7% and a tot
Stifel Client Assets Rise 3% in May, Driven by Recruiting, Market Gains
Express News | Stifel Reports May 2024 Operating Data
Investing in Stifel Financial (NYSE:SF) Five Years Ago Would Have Delivered You a 122% Gain
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. One great example is
MaaT Pharma Announces Initiation of Coverage of Its Stock by Stifel With a Buy Rating and a Target Price of EUR 16
LYON, France--(BUSINESS WIRE)--$MAAT--Regulatory News:MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Thera
Micron Stock Is on Fire. Analysts Say There's More Room for Gains.
Raymond James analyst Srini Pajjuri increased his price target for the chip stock to $160 from $130.
Comments
Stifel's regulatory oversight failure, indicated by the settlement, could impact its reputation and client trust. The firm's inability to ensure suitability of complex investment products for vulnerable groups like seniors could have long-term implications for its business model and client base.
Stifel Hit With $2.3 Million Penalty Over Sales of Complex Financial Products -- Barrons.com 2
The insider selling trend at Stifel Financial, even below the current price, might be perceived negatively as this implies insiders considered a lower price reasonable. Although there's a significant insider ownership, the recent sales discourage confidence in the company.
Stifel predicts economic rebound with sticky inflation and stable Fed rates to boost cyclic value and small cap stocks. But, inflated resurgence risk might endanger cyclical growth groups in the later half of next year.
1
On Monday, the $Nasdaq Composite Index(.IXIC.US$ dropped by 0.8% as various tech companies experienced decline including $NVIDIA(NVDA.US$ and $Meta Platforms(META.US$ which decreased by 2.7% and 1.5%, respectively. The $S&P 500 Index(.SPX.US$ and the $Dow Jones Industrial Average(.DJI.US$ also saw a decline amid recent hawkish commentary from the central bank.
Additi...
Additi...
16
Stifel Financial has seen more insider selling than buying in the past year which can serve as a warning sign. Although insiders own significant shares, more insider buying would be preferable, and there's one warning sign that deserves attention.
Read more